ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Valsartan

Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.

Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.

Drug pageValsartan: every studyMany companies study it; this page follows only the 125 they lead. All 254 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 10, 2005125 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1060 open or runningphase 4since Sep 10, 2005Nov 30, 2004none ahead
LG Chemits history only50 open or runningphase 3since Aug 5, 2013May 11, 2010none ahead
IlDong Pharmaceuticalits history only20 open or runningphase 3since May 20, 2014May 20, 2014none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Jul 21, 2014Jul 21, 2014none ahead
ARKAY Therapeuticsits history only10 open or runningphase 2since Sep 23, 2018Sep 23, 2018none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Aug 3, 2015Aug 3, 2015none ahead
EMSits history only10 open or runningphase 3since Nov 23, 2015Nov 23, 2015none ahead
Farma de Colombiaits history only10 open or runningphase 3since May 7, 2013May 7, 2013none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Jul 30, 2015Jul 30, 2015none ahead
Hanlim Pharm.its history only10 open or runningphase 1since Aug 2, 2018Aug 2, 2018none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Mar 16, 2006.

  1. Jul 20, 2010Phase 4 study in HypertensionNCT01167153 · 564 enrolled · China
  2. Nov 15, 2010Phase 4 study in Essential HypertensionNCT01241487 · 150 enrolled · Egypt
  3. Jan 20, 2011Phase 2 study in Isolated Systolic HypertensionNCT01281306 · 910 enrolled · United States, Argentina, Canada and more
  4. May 9, 2011Phase 3 study in HypertensionNCT01365481 · 150 enrolled · Colombia, Finland, Germany and more
  5. Aug 31, 2011Phase 1 study in HypertensionNCT01447485 · 12 enrolled · Japan
  6. Feb 23, 2012Phase 4 study in HypertensionNCT01541189 · 200 enrolled · China
  7. Jun 6, 2012Phase 3 study in HypertensionNCT01617681 · 127 enrolled · Belgium, Brazil, France and more
  8. Feb 12, 2014Phase 4 study in Essential HypertensionNCT02062645 · 115 enrolled · Turkey
  9. Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
  10. Dec 20, 2018Phase 3 study in Heart FailureNCT03785405 · 216 enrolled · United States, Argentina, Austria and more
  11. Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03988634 · 467 enrolled · United States, Canada
  12. Jul 10, 2019Phase 4 study in Chagas DiseaseNCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
  13. Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNCT04637555
  14. Nov 13, 2023Phase 3 study in Heart FailureNCT06149104 · 8 enrolled · Japan

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
TelmisartanruleBoehringer Ingelheimphase 4132
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The newest 60 of 106 Novartis leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT06149104Heart Failure · Japan3CompletedAug 14, 20248
NCT04637555Post Myocardial Infarction3WithdrawnJun 1, 20230
NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more4CompletedMar 16, 2025922
NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada3CompletedDec 14, 2022467
NCT03785405Heart Failure · United States, Argentina, Austria and more3CompletedDec 29, 2023216
NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more3CompletedOct 28, 20192,572
NCT02062645Essential Hypertension · Turkey4CompletedSep 2015115
NCT01617681Hypertension · Belgium, Brazil, France and more3CompletedJan 24, 2017127
NCT01541189Hypertension · China4CompletedJan 2013200
NCT01447485Hypertension · Japan1CompletedOct 201112
NCT01365481Hypertension · Colombia, Finland, Germany and more3CompletedSep 2015150
NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more2CompletedDec 2011910
NCT01241487Essential Hypertension · Egypt4CompletedJan 2011150
NCT01167153Hypertension · China4CompletedApr 2011564
NCT01001572Essential Hypertension3CompletedMay 2010932
NCT00939588Hypertension · Russian Federation2CompletedDec 200988
NCT00931710Isolated Systolic Hypertension · United States4CompletedJan 2010488
NCT00902304Hypertension · United States, Australia4CompletedJul 20112,337
NCT00821574Hypertension4CompletedMar 2007144
NCT00809926Hypertension · United States4CompletedJul 2009451
NCT00698646Hypertension · United States4CompletedJun 2009384
NCT00699192Hypertension · Czech Republic, Finland, France and more3CompletedMay 2009965
NCT00666536Hypertension · United States4CompletedJan 2009728
NCT00687973Hypertension · France4CompletedJan 2009393
NCT00700271Hypertension · France, Tunisia4CompletedAug 2008478
NCT00550095Proteinuria · Egypt4CompletedNov 2009509
NCT00548067Hypertension · India3Completed111
NCT00523744Hypertension · Germany3CompletedDec 2007257
NCT00523549Hypertension · United States4CompletedJan 2008229
NCT00487123Hypertension · Singapore4CompletedSep 2007
NCT00457626Hypertension · United States, Belgium, Brazil and more3CompletedMay 25, 200966
NCT00446563Hypertension · Germany3CompletedMar 201090
NCT00446524Hypertension · Japan3CompletedOct 2008403
NCT00446511Hypertension · United States, Belgium, France and more3CompletedJun 2009250
NCT00439738Hypertension · United States4CompletedNov 2007412
NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more3CompletedNov 20071,183
NCT00435162Hypertension · United States, Belgium, Brazil and more3CompletedJan 200974
NCT00433836Hypertension · United States, Belgium, France and more3CompletedFeb 2009300
NCT00426478Hypertension · Taiwan4Completed80
NCT00425997Hypertension · United States4CompletedOct 2007480
NCT00425373Essential Hypertension · Japan3CompletedMar 20081,474
NCT00416728Hypertension · United States1Completed32
NCT00416468Hypertension · United States1Completed32
NCT00415883Healthy · India1Completed40
NCT00413413Hypertension · China3CompletedNov 20071,134
NCT00413049Hypertension · China3CompletedNov 2007698
NCT00409851Hypertension · United States, Germany3CompletedMar 20051,293
NCT00409760Hypertension · Germany3CompletedFeb 20041,930
NCT00409643Hypertension · United States, Germany3CompletedJul 20041,259
NCT00409578Myocardial Ischemia · United States, Belgium, Canada and more2CompletedApr 20091,101
NCT00400777Hypertension · Brazil4CompletedNov 2007460
NCT00396656Hypertension · Germany, Switzerland3CompletedDec 200730
NCT00394745Hypertension · Germany, Switzerland3CompletedJun 200745
NCT00392262Hypertension · Germany, Switzerland3CompletedFeb 2007224
NCT00386607Hypertension · United States, Canada, Germany and more3CompletedJul 2008601
NCT00385931Hypertension · United States3CompletedApr 2003412
NCT00367939Hypertension · Germany3CompletedJul 2006132
NCT00360178Hypertension · Germany, Switzerland3CompletedDec 2006198
NCT00353912Hypertension · United States3CompletedApr 2007571
NCT00351130Hypertension · Germany, Switzerland4CompletedMar 200779

How it is read

Names in the registry

  • “Valsartan”, 31 entries
  • “valsartan”, 23 entries
  • “sacubitril/valsartan”, 5 entries
  • “valsartan plus hydrochlorothiazide”, 5 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.